SARM
GTX-027
SaveA next-generation SARM from GTx Inc. (now Oncternal Therapeutics), designed as a follow-up to enobosarm (ostarine) with improved selectivity for muscle and bone.
Quick verdict
Preclinical successor to ostarine. Very limited public data on human use.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
GTx developed this compound as an improved SARM candidate after ostarine's mixed Phase III results. Published data is primarily from patent filings and preclinical pharmacology. No published human efficacy trial results.
Benefits
- Designed for improved tissue selectivity over ostarine
- Preclinical anabolic activity in bone and muscle models
Dosage notes
No human dosing information publicly available.
Side effects
- Unknown in humans
- Expected hormonal suppression
Who should be cautious
Not approved for any use. Minimal human data available.
What this page cannot tell you
Clinical development status is unclear following GTx's corporate restructuring.
Leaderboard scores
- Muscle30
- Recovery20
Write a review
Sign in to write a review.